News
EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
Prague, March 8, 2022 – Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had…
Fexofenadine – Non-Sedative and Immunomodulatory Antihistamine in the Treatment of Allergic Symptoms
One of the biggest limitations of traditional antihistamines is the sedative effect on the central…
Does gliflozin treatment for heart failure have greater benefits in diabetics?
Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic market by…
Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight
Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma…
Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant…
Use of Specific Inhibition of Anticoagulant Therapy During Heart Transplantation
A recent report from real clinical practice summarizes the experiences of physicians with…
Micronized Diosmin Obtained Reimbursement, Based on Its Therapeutic Interchangeability with MPFF
On January 11, 2022, the State Institute for Drug Control (SÚKL) issued a decision on the…
Metamizole, even after 100 years on the market, remains an important component of postoperative pain therapy
Metamizole has been used in the therapy of a wide range of acute and chronic pains for 100 years.…
Administration of Erdosteine after Severe COVID-19 in the Early Period after Discharging Patients from the Healthcare Facility
Erdosteine is a mucomodulatory drug used in the treatment of various acute and chronic respiratory…
Even in Severe Cases of HAE, Individualized Treatment is Crucial – Case Study
As part of the case seminar from the HAExpert series, held on December 1, 2021, which specifically…